Rapport Therapeutics, Inc. (RAPP): Total Liabilities
$27.78M
As of 2025-12-31
$36.06M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.78M | +192.2% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $9.51M | -34.3% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $14.48M | n/a | 2025-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $27.78M | +192.2% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $122.11M | -24.0% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $54.87M | +30.6% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $16.69M | +20.9% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
Compare RAPP, RIGL, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗